|
| Thursday, December 15, 2022 |
|
|
Legend Capital Portfolio Company Bespin Global Completes USD100m Series D Financing |
| Legend Capital Portfolio Company Bespin Global, a Korea-headquartered cloud services company, has recently completed its Series D round financing of USD100 million, which will be used mostly for acquisitions. more info >> |
|
| Friday, December 9, 2022 |
|
|
Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing |
| Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as "GS Biotech") officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital. more info >> |
|
| Sunday, November 13, 2022 |
|
|
Legend Capital Portfolio Company Atour Successfully Lists on Nasdaq |
| On the evening of November 11, Beijing time, Legend Capital portfolio company Atour Lifestyle Holdings Limited ("Atour") was officially listed on the Nasdaq Stock Exchange in the United States. It has priced its initial public offering of 4,750,000 American Depositary Shares ("ADSs") at US$11.0 per ADS. more info >> |
|
| Thursday, November 10, 2022 |
|
|
Led by Legend Capital, PureFDA Secures Over CNY100 million in the Series B Round |
| Recently, PureFDA Medical Technology (Guangzhou) Co., LTD. (hereinafter referred to as "PureFDA") announced the completion of the Series B round of financing of over CNY100 million, which was led by Legend Capital and followed by the existing shareholder Bayland Capital. more info >> |
|
| Wednesday, November 9, 2022 |
|
|
君联资本所投企业巨子生物在港交所成功上市 |
| 据君联资本CEO Club报道，11月4日，君联资本所投企业巨子生物（2367.HK）在香港联交所主板成功上市。巨子生物拟全球发售2260.88万股，其中香港发售股份226.12万股，国际发售股份2034.76万股，另有15%超额配股权，发行价为24.3港元/股。 more info >> |
|
|
君聯資本所投企業巨子生物在港交所成功上市 |
| 據君聯資本CEO Club報道，11月4日，君聯資本所投企業巨子生物（2367.HK）在香港聯交所主板成功上市。巨子生物擬全球發售2260.88萬股，其中香港發售股份226.12萬股，國際發售股份2034.76萬股，另有15%超額配股權，發行價為24.3港元/股。 more info >> |
|
| Monday, November 7, 2022 |
|
|
Legend Capital Portfolio Company Giant Biogene Successfully Lists on the HKEX |
| On November 4, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange. more info >> |
|
| Tuesday, November 1, 2022 |
|
|
Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round |
| Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital. more info >> |
|
|
Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round |
| Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital. The fresh capital will be used for the R&D of Easy-Flow's peripheral intervention pipeline. more info >> |
|
| Thursday, October 20, 2022 |
|
|
Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round |
| VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital. more info >> |
|
|
|
|
